Bhumsuk Keam

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta et al. · Journal of Clinical Oncology · 2016 · 859 citations · Full text

Medicine, Oncology, Pharmacology +17

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Vivek Subbiah, Mimi I. Hu, Lori J. Wirth et al. · The Lancet Diabetes & Endocrinology · 2021 · 353 citations · Full text

Medicine, Endocrinology, Oncology +9

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

Marcia S. Brose, Bruce Robinson, Steven I. Sherman et al. · The Lancet Oncology · 2021 · 243 citations

Medicine, Oncology, Pharmacology +12

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

Janice M. Mehnert, Andréa Varga, Marcia S. Brose et al. · BMC Cancer · 2019 · 221 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

Robert I. Haddad, Tanguy Y. Seiwert, Laura Q.M. Chow et al. · Journal for ImmunoTherapy of Cancer · 2022 · 96 citations · Full text

Medicine, Immunology, Oncology +17